Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates
We have characterized an assay measuring CD8+ T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of HIV -1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immuno...
Main Author: | |
---|---|
Published: |
University of London
2012
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.577536 |
id |
ndltd-bl.uk-oai-ethos.bl.uk-577536 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-bl.uk-oai-ethos.bl.uk-5775362015-03-20T05:38:40ZDevelopment and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidatesSpentzou, Aggeliki2012We have characterized an assay measuring CD8+ T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of HIV -1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immunosorbent assay (ELlSA), avoids generation of T cell clones and can be performed with <2 million peripheral blood mononuclear cells. Efficient CD8+ T cell-mediated cross-clade inhibition of HIV-I replication in vitro was demonstrated in antiretroviral therapy-naive HIV -l-infected subjects with controlled viral replication in vivo but not in viremic subjects. The observed HIV-I inhibition is reversed by blockade of MHC I and physical separation of effector CD8+ and target CD4+ T cells by transwell chambers. An HIV-I vaccine candidate, consisting of adenovirus (Ad) serotype 35 vectors tested in a phase I clinical trial, induced CD8+ T cells that efficiently inhibited HIV -1. Assessment of direct antiviral T cell function by this assay provides additional information to guide vaccine design and the prioritizing of candidates for further clinical trials. 2616.979201University of Londonhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.577536Electronic Thesis or Dissertation |
collection |
NDLTD |
sources |
NDLTD |
topic |
616.979201 |
spellingShingle |
616.979201 Spentzou, Aggeliki Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates |
description |
We have characterized an assay measuring CD8+ T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of HIV -1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immunosorbent assay (ELlSA), avoids generation of T cell clones and can be performed with <2 million peripheral blood mononuclear cells. Efficient CD8+ T cell-mediated cross-clade inhibition of HIV-I replication in vitro was demonstrated in antiretroviral therapy-naive HIV -l-infected subjects with controlled viral replication in vivo but not in viremic subjects. The observed HIV-I inhibition is reversed by blockade of MHC I and physical separation of effector CD8+ and target CD4+ T cells by transwell chambers. An HIV-I vaccine candidate, consisting of adenovirus (Ad) serotype 35 vectors tested in a phase I clinical trial, induced CD8+ T cells that efficiently inhibited HIV -1. Assessment of direct antiviral T cell function by this assay provides additional information to guide vaccine design and the prioritizing of candidates for further clinical trials. 2 |
author |
Spentzou, Aggeliki |
author_facet |
Spentzou, Aggeliki |
author_sort |
Spentzou, Aggeliki |
title |
Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates |
title_short |
Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates |
title_full |
Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates |
title_fullStr |
Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates |
title_full_unstemmed |
Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates |
title_sort |
development and characterization of viral inhibition assay (via) : a cd8t cell neutralization assay for use in clinical trials of hiv-1 vaccine candidates |
publisher |
University of London |
publishDate |
2012 |
url |
http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.577536 |
work_keys_str_mv |
AT spentzouaggeliki developmentandcharacterizationofviralinhibitionassayviaacd8tcellneutralizationassayforuseinclinicaltrialsofhiv1vaccinecandidates |
_version_ |
1716793408935165952 |